Adrian Bot – författare

Wolf's discovery demonstrating that a reporter gene is expressed in myocytes subsequent to injection of naked DNA, was exploited by immunologists and vaccinologists to develop a new generation of vaccines. This observation galvanized the research and in a short lapse of time, an oceanic volume of knowledge has been accumulated. The research carried out in a variety of animal models showed the efficacy of genetic immunization against viruses, bacteria, and some parasites by the ability to induce a strong priming effect resulting from long-lasting persistence of plasmid as episomes. Furthermore, it was demonstrated that newborn or infant immune unresponsiveness to classical vaccines can be corrected by genetic immunization. The applications of genetic immunization for prophylaxis of infections was extended to immunotherapy, namely, cancerous, auto­ immune, and allergic diseases. Immunologists have provided pertinent information on the cellular basis of the immune responses elicited by genetic immunization, and molecular biologists have established the molecular basis of intrinsic adjuvant properties of plasmids.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: Challenges and Opportunities in Translation:Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Depending on the definition of this concept that is adopted, adolescence is the narrow threshold or a vast no-man's land that separates adulthood from childhood. In one -physica1ist- view, adolescence begins when secondary sex characters become noticeable and ends when they are fully developed. In another -socio1ogica1- view, adolescence ends when social independence has been gained. It may easily take many years more to span the interval between those two events. In this collection of papers by specialists from various disciplines, physical, psychological and social aspects of adolescence are considered. The book originates from a postgraduate course for medical practitioners, who deal with adolescents, but the range of the papers is such that we hope it may be of value to a much wider readership, including educators and all who are concerned with adolescents. The course was entitled: 'Adolescence: psychological, social and biological aspects', and was held in Leiden in November 1981. It was the fourth in a series of Boerhaave Courses instigated by the Dutch Growth Foundation of available. which a published record has now become Previous titles are 'Somatic growth of the child' (1966), 'De samenstel1ing van het mense1ijk 1ichaam' (1968) (=Human body composition), and 'Normal and abnormal development of brain and behaviour' (1971).VI The detailed programme of the course was planned by Dr. F.J. Bekker, Prof. Dr. J.L. van den Brande, Prof. Dr. W. Everaerd, Prof. A.Th. Schweizer and Prof. Dr. J.J. van der Werff ten Bosch.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: From Research to Clinical Practice: Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potential Discusses theranostics as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapy Presents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancer Reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: From Research to Clinical Practice:Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: Challenges and Opportunities in Translation is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: Challenges and Opportunities in Translation:Critically analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Wolf's discovery demonstrating that a reporter gene is expressed in myocytes subsequent to injection of naked DNA, was exploited by immunologists and vaccinologists to develop a new generation of vaccines. This observation galvanized the research and in a short lapse of time, an oceanic volume of knowledge has been accumulated. The research carried out in a variety of animal models showed the efficacy of genetic immunization against viruses, bacteria, and some parasites by the ability to induce a strong priming effect resulting from long-lasting persistence of plasmid as episomes. Furthermore, it was demonstrated that newborn or infant immune unresponsiveness to classical vaccines can be corrected by genetic immunization. The applications of genetic immunization for prophylaxis of infections was extended to immunotherapy, namely, cancerous, auto­ immune, and allergic diseases. Immunologists have provided pertinent information on the cellular basis of the immune responses elicited by genetic immunization, and molecular biologists have established the molecular basis of intrinsic adjuvant properties of plasmids.

Wolf''s discovery demonstrating that a reporter gene is expressed in myocytes subsequent to injection of naked DNA, was exploited by immunologists and vaccinologists to develop a new generation of vaccines. This observation galvanized the research and in a short lapse of time, an oceanic volume of knowledge has been accumulated. The research carried out in a variety of animal models showed the efficacy of genetic immunization against viruses, bacteria, and some parasites by the ability to induce a strong priming effect resulting from long-lasting persistence of plasmid as episomes. Furthermore, it was demonstrated that newborn or infant immune unresponsiveness to classical vaccines can be corrected by genetic immunization. The applications of genetic immunization for prophylaxis of infections was extended to immunotherapy, namely, cancerous, auto­ immune, and allergic diseases. Immunologists have provided pertinent information on the cellular basis of the immune responses elicited by genetic immunization, and molecular biologists have established the molecular basis of intrinsic adjuvant properties of plasmids.

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.Cancer Vaccines: From Research to Clinical Practice:Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potentialDiscusses "theranostics" as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapyPresents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancerReviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them

Recent advances in immunology and biology have opened new horizons in cancer therapy, included in the expanding array of cancer treatment options, which are immunotherapies, or cancer vaccines, for both solid and blood borne cancers. Cancer Vaccines: From Research to Clinical Practice is the first text in the field to bring immunotherapy treatments from the laboratory trial to the bedside for the practicing oncologist.

Cancer Vaccines: From Research to Clinical Practice:

Analyzes the most promising classes of investigational immunotherapies, integrating their scientific rationale and clinical potential Discusses theranostics as pertaining to immunotherapy, i.e., using molecular diagnostics to identify patients that would most likely benefit from a therapy Presents the new paradigm of biomarker guided R&D and clinical development in immunotherapy of cancer Reviews bottlenecks in translational process of immunotherapies and offers strategies to resolve them.